Analyst Ratings for Erasca Inc (ERAS)
ERAS Rating Summary
ERAS Price Target Summary
- Highest: $33.00 (JPMorgan)
- Lowest: $18.00 (Piper Sandler)
- Average: $23.50
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$23.50 (+40.2%)
* Over Last 12-Mos
Rating Score: 7.7 / 10
Percentile Rank: 81%
Avg. $ Target:
$23.50 (+40.2%)
* Over Last 12-Mos
Rating Score: 7.7 / 10
Percentile Rank: 81%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/13/2026 | Goldman Sachs | Kevin Strang | New Coverage | Early-Stage Biotech (N/A) |
N/A (N/A) |
18.53 (16.76) |
-9.55% | Details |
| 6/4/2026 | BofA Securities » Updated 8/14/2026 |
Alec Stranahan | Upgrade | Neutral (Underperform) |
20.00 (18.00) |
13.18 (16.76) |
27.16% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
